Vaccinex (VCNX) Competitors $0.79 -0.03 (-3.66%) As of 08/1/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCNX vs. BTAI, AIMD, BFRI, LSB, PHXM, XFOR, APRE, BMRA, IMNN, and KZIAShould you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include BioXcel Therapeutics (BTAI), Ainos (AIMD), Biofrontera (BFRI), LakeShore Biopharma (LSB), PHAXIAM Therapeutics (PHXM), X4 Pharmaceuticals (XFOR), Aprea Therapeutics (APRE), Biomerica (BMRA), Imunon (IMNN), and Novogen (KZIA). These companies are all part of the "pharmaceutical products" industry. Vaccinex vs. Its Competitors BioXcel Therapeutics Ainos Biofrontera LakeShore Biopharma PHAXIAM Therapeutics X4 Pharmaceuticals Aprea Therapeutics Biomerica Imunon Novogen BioXcel Therapeutics (NASDAQ:BTAI) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends. Which has more volatility & risk, BTAI or VCNX? BioXcel Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Do insiders & institutionals believe in BTAI or VCNX? 30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 21.2% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, BTAI or VCNX? Vaccinex has lower revenue, but higher earnings than BioXcel Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.27M3.66-$59.60M-$13.55-0.10Vaccinex$388K5.29-$20.25M-$48.27-0.02 Is BTAI or VCNX more profitable? Vaccinex has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -2,163.18%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-2,163.18% N/A -83.80% Vaccinex N/A N/A -383.58% Do analysts recommend BTAI or VCNX? BioXcel Therapeutics presently has a consensus target price of $42.60, indicating a potential upside of 3,009.49%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than Vaccinex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor BTAI or VCNX? In the previous week, BioXcel Therapeutics had 2 more articles in the media than Vaccinex. MarketBeat recorded 2 mentions for BioXcel Therapeutics and 0 mentions for Vaccinex. BioXcel Therapeutics' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score. Company Overall Sentiment BioXcel Therapeutics Neutral Vaccinex Neutral SummaryBioXcel Therapeutics beats Vaccinex on 8 of the 15 factors compared between the two stocks. Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCNX vs. The Competition Export to ExcelMetricVaccinexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.05M$785.88M$5.48B$9.54BDividend YieldN/A4.84%4.73%4.09%P/E Ratio-0.021.3728.8623.83Price / Sales5.2925.68371.7266.14Price / CashN/A19.5635.4557.96Price / Book-0.306.758.275.54Net Income-$20.25M-$3.67M$3.25B$259.28M7 Day Performance11.25%-4.92%-3.73%-4.68%1 Month Performance8.21%-0.41%4.29%4.36%1 Year Performance-84.90%15.62%25.87%17.89% Vaccinex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCNXVaccinex0.4509 of 5 stars$0.79-3.7%N/A-83.7%$2.05M$388K-0.0240Gap DownBTAIBioXcel Therapeutics3.6017 of 5 stars$1.70-6.1%$42.60+2,405.9%-91.7%$10.96M$1.85M-0.1390News CoverageUpcoming EarningsGap UpAIMDAinos0.8864 of 5 stars$2.68+3.9%N/A-25.3%$10.81M$20K-0.4240Upcoming EarningsAnalyst UpgradeBFRIBiofrontera1.6918 of 5 stars$1.07+0.9%$2.75+157.0%-8.0%$10.75M$37.32M-0.4770Positive NewsLSBLakeShore Biopharma0.4206 of 5 stars$0.93-18.9%N/A-84.2%$10.70M$80.82M0.00773News CoverageShort Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049XFORX4 Pharmaceuticals4.5103 of 5 stars$2.13+17.0%$72.33+3,295.9%-93.1%$10.53M$2.56M0.9980Upcoming EarningsGap DownHigh Trading VolumeAPREAprea Therapeutics2.8263 of 5 stars$1.88-0.4%$15.50+723.7%-55.4%$10.45MN/A-0.797Gap UpBMRABiomerica0.2073 of 5 stars$3.66-6.5%N/A+31.3%$9.95M$5.41M-1.5860Positive NewsIMNNImunon2.4583 of 5 stars$7.21+3.0%$232.50+3,124.7%-57.7%$9.95M$500K-0.3530Upcoming EarningsDividend AnnouncementStock SplitKZIANovogen2.7573 of 5 stars$8.57-12.7%$14.00+63.4%-53.2%$9.89M$1.51M0.0012News CoverageShort Interest ↑ Related Companies and Tools Related Companies BTAI Competitors AIMD Competitors BFRI Competitors LSB Competitors PHXM Competitors XFOR Competitors APRE Competitors BMRA Competitors IMNN Competitors KZIA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCNX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
